Neurizon Therapeutics Limited (ASX:NUZ)

Neurizon Therapeutics Revenue

In the fiscal year ending June 30, 2026, Neurizon Therapeutics had annual revenue of 17.59M AUD with 1,043.54% growth. Neurizon Therapeutics had revenue of 11.61M in the half year ending June 30, 2026.

• Revenue: 17.59M
• Revenue Growth: +1,043.54%
• P/S Ratio: 3.44
• Revenue / Employee: 4.40M
• Employees: 4
• Market Cap: 60.46M

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2026	17.59M	16.05M	1,043.54%
Jun 30, 2025	1.54M	696.12K	82.70%
Jun 30, 2024	841.71K	-31.94K	-3.66%
Jun 30, 2023	873.65K	-3.64M	-80.63%
Jun 30, 2022	4.51M	853.24K	23.33%

Data Source: S&P Global Market Intelligence Last updated: Aug 25, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 8, 2026

Data Sources Report a data error